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INTRODUCTION
Trypanosoma cruzi, the parasitic protozoan that causes American trypanosomiasis (known also as Chagas disease), has a functional pentose phosphate pathway (PPP) [1] . This pathway has been proposed to have crucial roles in the protection of trypanosomatids against oxidative stress, as well as in the production of nucleotide precursors [2] . All seven enzymes of the PPP can be detected in all four major stages in the biological cycle of the parasite, i.e. the epimastigote and the metacyclic trypomastigote in the insect vector, and the intracellular amastigote and the bloodstream trypomastigote in the infected mammal [1] .
The PPP consists of two branches. The oxidative branch leads from D-glucose 6-phosphate to D-ribulose 5-phosphate, with the reduction of two molecules of NADP. The non-oxidative, or sugar interconversion, branch ultimately leads back to glycolytic intermediates. Ribose-5-phosphate isomerase (Rpi, EC 5.3.1.6) is a key activity of the non-oxidative branch, catalysing the reversible aldose-ketose isomerization of D-ribose 5-phosphate (R5P) and D-ribulose 5-phosphate (Ru5P), see Fig. 1A . The mechanism is believed to involve two steps, an initial opening of the ring form of the sugar most common in solution, followed by the actual isomerization, which is thought to proceed via a cis-enediolate high energy intermediate.
Known Rpis belong to two completely unrelated protein families, both of which are represented in Escherichia coli [3, 4] . One of them, RpiA, is a constitutively expressed 23-kDa protein, whereas the other, RpiB, is a 16-kDa protein that is under the control of a repressor [5] [6] [7] . Expression of either enzyme allows normal growth of the bacterium, but growth of the double mutant rpiA -/rpiB -is severely impaired under all experimental conditions tested, showing that the reaction itself is very important for the bacterium [7] . Furthermore, at least one of the known types of Rpi can be identified in every genome sequenced to date. RpiAs are broadly distributed, being found in most eukaryotic organisms, and some prokaryotes. Inspection of the protein family database Pfam [8] shows that RpiBs (accession number PF02502) exist almost exclusively in prokaryotic organisms; there are a few exceptions in lower eukaryotes, including some trypanosomatids and other parasitic protozoa, as well as some fungi. RpiB-like sequences have also been reported in certain plants, but these are fused to a DNA-damage-repair/toleration protein, and lack some amino acid residues that are linked to binding the substrates.
We recently reported that T. cruzi has only a B-type Rpi, which we cloned, expressed and characterized, showing that Cys69 is essential for the isomerization, and that His102 is required for the opening of the furanose ring of R5P [9] . Since RpiBs are absent in all mammalian genomes sequenced so far, this enzyme can be considered as a possible target for the development of new chemotherapeutic agents against the parasite; as the active sites of RpiAs and RpiBs are completely different, the design of highly selective inhibitors should be possible [10] .
Among RpiBs for which biochemical data are available, the sequence of TcRpiB was found to be most similar to that of EcRpiB (~40% amino acid identity); it was therefore considered probable that, like EcRpiB, TcRpiB would be able to isomerize the 6-carbon sugars D-allose 6-phosphate (All6P) and D-allulose 6-phosphate (Allu6P), in addition to the R5P/Ru5P pair [11, 12] , see Fig. 1 . This, however, is not a common property of all RpiBs; the Mycobacterium tuberculosis enzyme (MtRpiB) is F o r R e v i e w O n l y 4 able to isomerize All6P only with an extremely low catalytic efficiency [13] . We considered it important, therefore, to perform further studies on TcRpiB specificity. In addition, our previous attempts to identify lead compounds in the development of new drugs against Chagas disease used homology modelling based on EcRpiB; given the moderate sequence identity of the template, it was clearly desirable to obtain the actual 3D-structure of TcRpiB.
We report here that TcRpiB is not able to isomerize All6P, which instead acts as a weak competitive inhibitor of the R5P/Ru5P isomerization. Further, the determination of x-ray structures of wild type and C69A mutant TcRpiB, with and without bound substrate and inhibitors, allowed us to study in detail the interactions between the enzyme and bound ligands, as well as small conformational changes associated with binding. These studies revealed that the differences in substrate specificity among RpiBs are at least partially due to changes in the structure of a phosphate-binding loop bordering the active site. Mutation of this loop to make it more like that of EcRpiB gave TcRpiB the ability to isomerize All6P. These studies expand our understanding of RpiBs in general, and provide a solid basis for future drug development against T. cruzi in particular.
RESULTS

Kinetic studies of wild type TcRpiB
The ability of TcRpiB-wt to isomerize All6P was tested using a discontinuous assay that measures the concentration of Allu6P after derivatization [13] . Isomerization of this 6-carbon sugar could not be detected, even when it was added at a concentration of 30 mM.
The same preparation of TcRpiB had a k cat of 28 s -1 and a K m of 5 mM when R5P was the substrate, measured directly using the absorption of Ru5P at 290 nm [14] . The Lineweaver-Burk plot presented in Fig. 2 shows that, when added to the R5P-Ru5P isomerization reaction of TcRpiB, All6P produces the pattern expected for a competitive inhibitor (K i = 15 mM).
A number of inhibitors that mimic the 6-carbon high-energy intermediate expected for an All6P/Allu6P isomerization [15] were tested, i.e. 5PRH, 5PRA, 5PRAm, 5PRMA and 5PRGly. None of these compounds inhibited TcRpiB significantly, even at concentrations as high as 10 mM. Phosphate did not inhibit at concentrations up to 100 mM.
Structures of TcRpiB and ligand binding
TcRpiB (wild type or a C69A mutant) was crystallized alone or in the presence of a relevant ligand: phosphate, R5P, 4PEH or All6P (see Fig. 1 ). Data collection and refinement statistics for the five structures solved are summarized in Table 1 . All crystals diffracted to high resolution. Most of them exhibited the same space group (P4 2 2 1 2, with two molecules in the asymmetric unit) with similar cell dimensions; TcRpiB-R5P (P2 1 2 1 2, with four molecules in the asymmetric unit) was the exception. Each molecule could be traced from residues 1-2 to 152-153 (of a total of 159). The N-terminal 6-His tag (20 residues) was never observed in the electron density. Superimposing the molecules within the various asymmetric units showed that they are very similar, with pair-wise root-mean-square (r.m.s.) differences of 0.1-0.2 Å when all C α atoms were compared. When aligned using a tighter cut-off (0.5 Å), only The relatively weak electron density for this segment also suggested some mobility, and in some cases, the conformation could be influenced slightly by crystal packing. However, the stated conclusions apply, regardless of which molecules were used in the comparisons.
For the structures in the P4 2 2 1 2 space group, the two molecules of the asymmetric unit form a homodimer (Fig. 3A) , the major species observed during size exclusion chromatography [9] . Each subunit is based on a Rossmann fold with a five-stranded parallel -sheet flanked by five α-helices, two on one side and three on the other. The sixth (C-terminal) 〈-helix extends from the main fold and interacts with the second subunit to stabilize the dimer. Dimers interact via crystallographic symmetry to form tetramers. Each subunit of the dimer interacts with both subunits of the second dimer. Hence, residues 113-122 interact with the equivalent regions in one subunit of the second dimer, while residues 92-95 make contacts with their equivalents in the other subunit of the second dimer (Fig. 4A ). In the P2 1 2 1 2 (TcRpiB-R5P) case, the four molecules in the asymmetric unit represent the tetramer.
The two active sites of the functional dimer are located in clefts between the subunits, with components drawn from each; residues with numbering less than 100 (with the exception of Arg113) from one molecule function together with later residues in the sequence of the other. Strong electron density was seen in both active sites of the wild-type ligand-free structure (Fig. 3B) , apparently attached covalently to the active site base, Cys69. In further experiments, reducing agent was included, and protein samples were processed quickly, to avoid potential oxidation of the protein, or reaction between the protein and reducing agent.
The inactive C69A mutant was first crystallized in the presence of high concentrations of phosphate (0.8 M). The observed electron density supported the presence of the ion in each active site (Fig. 3C) , although probably at half occupancy. The phosphate, which is largely exposed to solvent, interacts with His11 and Arg113 from one molecule of TcRpiB, together with Arg137' and Arg141' (where the prime indicates residues from the other subunit of the functional dimer). We note, however, that multiple conformations of Arg113 are observed in this and all other TcRpiB complex structures. Thus this side chain can also interact with Glu112 of the same subunit or Glu118 of a crystallographically-related subunit in the tetramer interface. These multiple conformations do not seem to be related to significant differences elsewhere.
When TcRpiB-wt was crystallized in the presence of R5P, electron density in the active site clearly showed that a linear sugar molecule was bound (Fig. 3D) . Again, the phosphate group interacts with His11, Arg113, Arg137' and Arg141'. The other end of the substrate points into a deep pocket in the enzyme. Moving along the ligand from the phosphate, O4 interacts with His102' and a water molecule that is in turn within hydrogen-bonding distance of Tyr46, His138' and Arg141'. O3 hydrogen bonds to Asp10, as well as to the backbone amide nitrogen of Gly70. O2 hydrogen bonds with water, and the backbone nitrogen of Ser71. At the far end, O1 interacts with Asn103', and the backbone nitrogen of Gly74. TcRpiB-wt was also crystallized with the linear inhibitor, 4PEH ( Fig. 3E ; K i 1.2 mM [9] ). Hydrogen bonds to the phosphate group are as described above. The O2 and O3 of 4PEH correspond to O3 and O4 of the R5P structure (see Fig. 1 ). Accordingly, O3 of 4PEH interacts with His102' and a water molecule, while O2 hydrogen bonds to Asp10 and to the backbone amide nitrogen of Gly70. O1 of 4PEH interacts with the backbone nitrogen of Ser71 as seen for the O2 interaction in R5P. As for O1 of R5P, the terminal group of the inhibitor has hydrogen bonds to Asn103' and the backbone nitrogen of Gly74; however, in the 4PEH structure, the distance between O N and Gly74 is shorter (2.7 Å, average of both subunits) than the equivalent distance in R5P (3.0 Å, average of four subunits). The structure of TcRpiB-C69A bound to 4PEH was identical to that of the wild type complex (not shown).
TcRpiB-C69A was further crystallized with the weaker inhibitor, All6P (K i 15 mM). Electron density for this ligand (Fig. 3F ) was noticeably poorer in both active sites than was seen for other complex structures. The phosphate group lies at the same place, but the rest of the sugar is much less well defined. The electron density suggests that All6P is bound primarily as the linear form, although with mixed binding modes. This density did not improve after cyclic averaging, or when higher concentrations of All6P (up to 50 mM) were included; for these reasons only the phosphate moiety of the sugar has been modelled in the structure deposited.
Comparison of TcRpiB structures
The various structures of TcRpiB exhibited r.m.s. differences in the range of 0.15 -0.3 Å when their C α atoms were aligned, with most atoms matching within a 0.5 Å cut-off.
When comparing TcRpiB-wt (the ligand-free structure) to the complexes with R5P or 4PEH, the most striking difference is a 1.5 -1.8 Å movement of the main chain at residues 10-12. Asp10 and His11 interact with R5P and 4PEH in similar ways, drawing this segment further into the active site pocket. The movement is coupled to changes in the mobile loop at residues 42-45.
The close similarity between TcRpiB-C69A/Pi and TcRpiB-C69A/All6P indicates that binding phosphate and All6P (of which only the phosphate group is ordered in the electron density) have equivalent effects on the protein. The conformation observed for the mobile loops in these structures is midway between that for the apo/Pi and R5P/4PEH structures, presumably because the phosphate ion interacts with His11, but not Asp10.
Other differences include alternative side-chain conformations that were modelled for His102 and Arg113. The side chain of His102 in TcRpiB-wt is turned ~90° compared to the same residue in the rest of the structures. This residue also has multiple conformations in both structures of mutated protein, i.e. TcRpiB-C69A/Pi and TcRpiB-C69A/All6P. In all TcRpiB complex structures presented here, Arg113 has two different conformations, one pointing towards the phosphate group of the ligand, and the other pointing out into solution. In the TcRpiB-wt (i.e. ligand-free) structure, Arg113 is only in the latter conformation (Fig. 3) . TcRpiB is compared to structures found in the PDB (including three that are unpublished) in Table 2 and Fig. 4 . The majority of Cα atoms match within a 2-Å cutoff when the dimers are compared. As in TcRpiB, a helix at the C-terminus of EcRpiB, TmRpiB and CtRpiB (unpublished) is an important component of the dimer interface. In MtRpiB, an extension at this end of the protein produces additional interactions that stabilize the dimer. An even longer extension is found in SpRpiB and NaRpiB (both unpublished), but serves primarily to enlarge the structure of the subunit, rather than enhancing dimer interactions. All but MtRpiB form a dimer of dimers (i.e. a tetramer), as a result of crystallographic and/or non-crystallographic symmetry. As for TcRpiB, EcRpiB and TmRpiB tetramers are the consequence of interactions of two segments from each subunit (Fig. 4A) . CtRpiB is described as a dimer in the PDB header, but a comparable tetramer is formed by crystallographic symmetry. NaRpiB has a 4-residue insertion near residue 116 of TcRpiB, and in the resulting tetramer, the second dimer is similarly placed, but with a different "tilt" relative to the first, compared to the above-named structures (Fig. 4B) . SpRpiB is described as a dimer in the PDB header, but our analysis suggests that it actually forms a tetramer via crystallographic symmetry that is very similar to the one found in NaRpiB.
Comparison of TcRpiB to other structures
In Fig. 5A , the binding of R5P in the active sites of TcRpiB and MtRpiB is compared. Interactions with the substrate are almost completely conserved. The most noteworthy difference is that, in TcRpiB, the catalytic base that transfers a proton between C1 and C2 in the isomerization step is a cysteine (Cys69), while in MtRpiB, the base is a glutamic acid (Glu75) originating later in the sequence, but terminating in the same position. The simultaneous transfer of a proton between O1 and O2 is catalysed by the side chain of Ser71 in both cases. Both enzymes also have the Gly70-Gly74 segment that creates an anion hole stabilizing the cis-enediolate intermediate of the reaction. Arg113, a phosphate ligand in the MtRpiB structure, has a different conformation in TcRpiB, but is free to assume a conformation that allows phosphate interactions.
The active site of TcRpiB/R5P is compared to the EcRpiB/apo structure in Fig. 5B . Both enzymes include an active-site cysteine, and the serine (or threonine) and anion hole components are also highly similar. Because these groups are responsible for the catalytic steps, we use them as anchor points in the alignments, when considering differences in the rest of the active site that might be linked to substrate specificity. Interactions with Asp10 and His11 (TcRpiB numbering) are likely to be preserved, although these residues probably move when substrate binds, as noted for the TcRpiB structures above. Arg40 of EcRpiB provides a potential interaction with the phosphate of the substrate that is not present in either TcRpiB or MtRpiB, but might be more suitable for a substrate longer than R5P. Again, the equivalent of Arg113 is observed in different conformations in the various structures. Residues drawn from the second subunit of the dimer differ more in position relative to the catalytic residues. However, the most striking change is linked to a deletion in the EcRpiB sequence (one residue near 135 in TcRpiB numbering) that moves the equivalents of Arg137 and His138 further away from the catalytic residues; this loop will be referred to as the 137-loop in further discussion. This change could additionally affect the relative position of His102.
SpRpiB and NaRpiB are less straightforward to compare. The Cα atoms at the anion hole, including those of the catalytic cysteine and threonine, align very well, and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r R e v i e w O n l y 8 residues equivalent to Tyr46 and Asn103 in TcRpiB are also conserved. However, Asp10 of the T. cruzi enzyme is replaced by a glutamate in both SpRpiB and NaRpiB, and His11, His102 and His138 are also absent in these two proteins. Further, an insertion in the 137-loop remodels several aspects of the putative phosphate-binding site.
Deletion mutation of TcRpiB (∆ 135 E136G) A mutation experiment was undertaken to create a version of TcRpiB that was more similar to EcRpiB in the above-mentioned 137-loop, i.e. ∆ 135 E136G. Kinetic analysis indicated that the mutant enzyme had a k cat of 0.15 ± 0.06 s -1 , and a K m of 0.8 ± 0.1 mM for the All6P isomerase activity (Fig. 6 ). When using R5P as a substrate, the k cat of the mutant protein was 16 s -1 , and the K m was 7 mM.
DISCUSSION
We previously experienced problems obtaining complexes of EcRpiB [13] , a frustrating contrast to the situation with MtRpiB [13, 16] . The difference is attributable to a highly reactive active-site cysteine in EcRpiB. We note further that, in the TmRpiB and NaRpiB structures, the active-site cysteine was oxidized (modelled as cysteine sulfonic acid and cysteine-S-dioxide, respectively), which may be correlated with the lack of complexes for these enzymes, as well (Table 2) . Here, we solved a similar problem with TcRpiB (Fig. 3B ) by including β-mercaptoethanol (β-ME) in the various protocols, and working quickly. The modified procedure allowed us to obtain clear electron density for a number of complexes ( Fig. 3C-F ). In the case where R5P was added, the sugar in the active site is expected to be a mixture of R5P and Ru5P. In solution, R5P is present at ~3-fold higher concentrations than Ru5P [17] ; however, it is not possible to make a reliable estimate of the proportions bound to the protein based on the electron density, because of the strong similarity of the two sugars.
Our kinetic data show that TcRpiB has values of k cat and K m similar to those reported earlier (12 s -1 and 4 mM, respectively [9] ), and consistent with those normally observed for other RpiBs (Table 3 ). The 6-carbon sugar, All6P, is not a substrate for TcRpiB, even at a concentration of 30 mM. Considering the sensitivity of the assay, this suggests that k cat in this case is 0.015 s -1 or less, if K m is 20 mM or less. All6P instead acts as an inhibitor of TcRpiB's R5P/Ru5P isomerization (K i = 15 mM). However, in the structure with the TcRpiB-C69A mutant, clear electron density was only seen for the phosphate group of All6P. In light of this, one might ask whether the phosphate group accounts for most of the All6P inhibition. Phosphate alone is a very poor inhibitor; no inhibition was observed when it was added at concentrations as high as 100 mM, and the electron density in the complex with phosphate suggests only partial occupancy, indicating that the K i is of the order of 800 mM. Comparison of the available RpiB structures suggests that allosteric changes do not occur purely as a result of phosphate binding. This type of behaviour has been reported for other enzymes that act on phospho-sugars, even when interactions with the phosphate group account for most of the binding energy; in the case of triose phosphate isomerase, phosphate alone inhibits only weakly, but the phosphate moiety of the substrate is necessary for allosteric changes that make binding much tighter in the transition state [18] . The swap of the catalytic base (i.e. cysteine/glutamate) does not change how the enzymes interact with the 5-carbon substrates; the R5P/Ru5P complexes of TcRpiB and MtRpiB are highly similar (Fig. 5A ) Thus, a difference in the base does not explain why EcRpiB can effectively catalyze the All6P/Allu6P conversion, but TcRpiB and MtRpiB cannot. Changes in a loop that includes Arg137 (the 137-loop) that make the active site longer in the E. coli protein offered a more promising explanation (Fig. 5B) ; a similar loop in CtRpiB is also associated with an ability to act on both 5-and 6-carbon (non-phosphorylated) sugars [19, 20] . This hypothesis was tested by mutation. EcRpiB has a glycine instead of two glutamic acid residues just prior to the Arg137 of TcRpiB and MtRpiB (Fig. 7) . A TcRpiB mutant protein was therefore constructed that has the same sequence as EcRpiB in this loop, i.e. with a glycine replacing Glu135 and Glu136. The isomerization of R5P/Ru5P was not significantly changed in the ∆ 135 E136G mutant (see Table 3 ). However, unlike wild type TcRpiB, this mutant enzyme was able to isomerize the 6-carbon sugar (Fig. 6 ), although not with high efficiency. Clearly, other features of the structures must modulate the specificity of EcRpiB, but our results strongly suggest that the nature of the 137-loop is an important factor. We predict that TmRpiB and CtRpiB, which have a shorter 137-loop like that of EcRpiB (and a cysteine base), will also be able to isomerize All6P. SpRpiB and NaRpiB are unpublished structures described at the PDB as (putative) RpiBs. However, we are not aware of any biochemical data concerning these enzymes' activity, and a comparison of site-active features, as described in the Results section and illustrated in Fig. 7 , suggests that this is not their functional role. Both of these genomes also have an EcRpiB-like enzyme, and Streptococcus has an RpiA as well, meaning that Rpi activity is not a requirement for either SpRpiB or NaRpiB.
Two earlier reports concerning the completely unrelated family of β-barrel enzymes are relevant here. First, for triose phosphate isomerase (which catalyses an aldose/ketose isomerization similar to that of RpiBs), most of the rate acceleration in catalysis is derived from the energy of binding the phosphate group, which is accomplished via conformational changes in the enzyme [18] . Second, for the epimerization at carbon 3 catalyzed by the metal-dependent enzymes D-ribulose 5-phosphate 3-epimerase (which accepts only 5-carbon substrates) and D-allulose 6-phosphate 3-epimerase (which can accept both 5 carbon and 6 carbon substrates), changes in the length and/or structure of the phosphate-binding loop are linked to changes in sugar preferences, primarily expressed as differences in k cat [21] . It appears that the relationships between k cat and K m in enzymes catalyzing this type of reaction are unusually intimate and complex.
In accord with the lack of All6P isomerase activity, none of the compounds that mimics the 6-carbon high-energy intermediate expected for an All6P/Allu6P isomerization [15] inhibited TcRpiB. Some of these compounds do inhibit MtRpiB [13] . The difference in the behaviour of the two enzymes seems to arise from the slightly broader active site in MtRpiB, due to the switch of the catalytic base. As a result, the longer linear inhibitors can bind slightly more deeply in the MtRpiB active site than the R5P substrate, in a manner that is blocked by Cys69 of TcRpiB. The broader active site also enables All6P to bind as the ring form in the structure with MtRpiB, in contrast to the disordered (and probably linear) sugar observed here for TcRpiB (Fig. 3F ). Although the dimer comprises a complete functional unit, tetramers are observed in all available RpiB structures except that of MtRpiB (Fig. 4A, B and Table 2 ). There does not appear to be any aspect of this fold that requires a tetramer for stability. Further, gel filtration experiments at lower protein concentrations typically show dimers as the major form in solution. Although larger aggregates will be favoured at the higher protein concentrations in the crystallizations, the consistency with which highly similar tetramers are observed is intriguing. The reason may lie in the structure of some larger functional assembly as yet unknown.
We wished to establish the relative frequency of particular features in RpiB sequences. In Fig. 7 , the sequences of the structures discussed here are aligned, together with others that are representative. . We conclude that EcRpiB-like sequences are biased towards enzymes expected to process both R5P/Ru5P and 6-carbon sugars, while for MtRpiB-like sequences, the 5-carbon sugars are more likely to be the substrates of interest. It is noteworthy that the LacA subunit from the galactose-6-phosphate isomerase (that which contributes its C-terminal part to one active site, with the cysteine base provided by the N-terminal part of LacB) has the GGRH pattern, consistent with its role in processing 6-carbon sugars. The function of the second active site of the LacAB heterodimer is not yet clear; it is lined with residues well conserved within the LacAB family, but different from those of RpiB.
Little information exists concerning the ability of various organisms to metabolize Dallose or D-allulose (also known as D-psicose). E. coli, which can grow on D-allose as a carbon source, is an enteric organism, and so the ability to use this rare sugar may offer a biological advantage, given that it is not metabolized by the host, and in fact acts as an immunosuppressant [22] . Of the 8 organisms with glutamate-base enzymes including a shorter 137-loop, we could only find data for the marine bacterium Reinekea, which can metabolize D-allulose [23] . This organism is unusual in that it has an RpiA in combination with the Mt-type RpiB enzyme. However, D-allose and D-allulose are sufficiently rare that other 6-carbon sugars should be considered as the "real" substrates of this class of enzyme. Two recent studies showed that CtRpiB, which has the shorter 137-loop, is able to isomerize a number of 5-and 6-carbon sugars that lack phosphate groups. Best among the sugars tested (and better than Dribose and D-allose) was L-talose, with a physiologically uninteresting K m of 37 mM, but a k cat of 13500 s -1 at 65 °C [19, 20] ; higher affinity might well be observed with In this work we show how small differences in the RpiB sequences are linked to substantial effects on substrate specificity as well as inhibition patterns of the respective enzymes. Such information will be of great importance in designing new and highly specific RpiB inhibitors, ones that will not interact with the completely different active site of human RpiA.
EXPERIMENTAL PROCEDURES
Chemicals and reagents R5P was purchased from Sigma, and MESNA (sodium 2-mercapto-ethanesulfonate) was from Fluka Chemie GmbH. Oligonucleotide primers were provided by Gibco, Life Technologies. Restriction endonucleases were ordered from New England Biolabs. E. coli strain BL21 codon Plus (DE3) and the QuickChange TM site-directed mutagenesis kit were purchased from Stratagene. The compounds All6P, 5PRH (monohydroxylammonium salt), 5PRGly (trisodium salt), 5PRMA (disodium salt), 5PRAm (disodium salt), 5PRA (trisodium salt) and 4PEH were the kind gifts of Laurent Salmon, University of Paris-Sud (Orsay, France), and prepared as described previously [15, 16] .
Site directed mutagenesis
The TcRpiB mutant ∆ 135 E136G was constructed by PCR using methods described previously [9] , with the mutagenic primers, 5'CCG TTT AGC GGC GGG CGC CAT GTA CGA CG 3' and 5' CGT CGT ACA TGG CGC CCG CCG CTA AAC GG 3'.
Protein purification
Proteins were over-expressed and purified as described earlier [9] , with an added step consisting of size-exclusion chromatography (Hiload TM 16/60 Superdex TM 75, Pharmacia Biotech) on a column equilibrated with 20 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1 mM EDTA (adjusted to pH 8), 10 mM β-ME. Most other buffers, starting with the cell disruption step, also contained β-ME, but at 1 mM concentration. The exceptions included the first trials with wild type protein, and later work with the C69A mutant.
Kinetic assays
For kinetic assays, the buffer was changed to 50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 5 mM MESNA. R5P isomerase activity was tested by the spectrophotometric assay described by Wood [14] , in which the production of Ru5P is monitored directly as a change in absorbance at 290 nm (ε = 72 M −1 cm −1 ). All6P isomerase activity was tested by a modified version (scaled down 10-fold) of the TBA assay described earlier [13] . This assay mixture contained 50 mM Tris-HCl, pH 7.6, 5 mM MESNA and All6P, in a final volume of 100 µL. Following pre-incubation at 30 °C for 5 min, the reaction was initiated by the addition of 10 µL enzyme solution (0.83 mg/mL). After 3 min, the reaction was stopped by the addition of 100 µL concentrated HCl; after mixing, 100 µL 20 mM TBA in concentrated HCl (prepared fresh daily) was added. Initial rate conditions were confirmed using a control with half the enzyme; a blank of identical composition, but without enzyme, was used as the reference. Following dehydration, dephosphorylation, and reaction with TBA, a characteristic yellow TBA adduct of Allu6P is formed that strongly absorbs at 438 nm (ε = 27,800 M −1 cm −1 ). Crystallization Prior to crystallization, protein solutions (in 20 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1 mM EDTA (pH 8), 10 mM β-ME) were concentrated to 10 mg/mL and 16 mg/mL for TcRpiB-wt and TcRpiB-C69A, respectively. Screening of crystallization conditions was carried out by the sitting-drop vapour-diffusion method, using a Douglas Instruments Oryx robot together with a XYZV Plate Loader. For cocrystallization with 4PEH and R5P, the protein was mixed with ligand (dissolved in water) to give a final ligand concentration of 20 mM. For the TcRpiB-C69A/All6P structure, the concentration of ligand was 10 mM, and no reducing agent was added. Structure solution and refinement X-ray data (Table 1) were collected at the European Synchrotron Radiation Facility (ESRF), Grenoble, indexed using MOSFLM [24] and processed with SCALA [25] , as implemented in the CCP4 interface [26] .
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